Company: ZVRA
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001437749-25-016523
Chunk: 68

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 68
---
)  (735)
 Fair value adjustment related to warrant and CVR liability   4,874   3,627 
 Fair value adjustment related to investments   (3)  (27)
 Interest and other income, net   543   929 
 Total other income   3,445   3,794 
 Income (loss) before income taxes   (1,917)  (16,692)
 Income tax (expense) benefit   (1,182)  70 
 Net loss  $(3,099) $(16,622)
         
 Basic and diluted net loss per share of common stock:         
 Net loss  $(0.06) $(0.40)
         
 Weighted average number of shares of common stock outstanding:         
 Basic and diluted   54,095,543   41,778,774 

See accompanying notes to unaudited condensed consolidated financial statements.

       5

      Table of Contents

ZEVRA THERAPEUTICS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(in thousands)

      Three months ended March 31,  
   2025    2024  
 Net loss  $(3,099) $(16,622)
 Other comprehensive (loss) income:         
 Foreign currency translation adjustment   (713)  184 
 Other comprehensive (loss) income   (713)  184 
 Comprehensive loss  $(3,812) $(16,438)

See accompanying notes to unaudited condensed consolidated financial statements.

       6

ZEVRA THERAPEUTICS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(in thousands)

       Additional 

       Treasury 

       Other 

       Total 

       Common 

       Paid-in 

       Stock, 

       Accumulated 

       Comprehensive 

       Stockholders' 

       Stock 

       Capital 

       at cost 

       Deficit 

       Income (Loss) 

       Equity 

       Balance as of January 1, 2025 
       
      $
      5

      $
      555,302

      $
      (10,983
      )
       
      $
      (505,289
      )
       
      $
      631

      $
      39